7-23 | As the annual global HIV/AIDS conference gets underway in Amsterdam, Médecins Sans Frontières (MSF) called out ViiV Healthcare—a division of US and UK pharmaceutical corporations Pfizer and GlaxoSmithKline plus Japan’s Shionogi—for preventing children with HIV from getting child-appropriate formulations of a critical HIV medicine, dolutegravir. The World Health Organization (WHO) now recommends dolutegravir as a preferred treatment option for adults and for children from four weeks to ten years of age, to replace pediatric treatments containing sub-optima
7-20 | RCEP trade deal could cut medicines lifeline for people in developing countries As the sixteen countries negotiating Regional Comprehensive Economic Partnership (RCEP) trade agreement meet in Bangkok this week for another round of closed door negotiations, public health experts and the international medical humanitarian organization - Médecins Sans Frontières (MSF) warn that inclusion of any harmful intellectual property provisions in the agreement could have a severely negative impact on access to affordable generic medicines.
7-20 | RCEP trade deal could cut medicines lifeline for people in developing countries As the sixteen countries negotiating Regional Comprehensive Economic Partnership (RCEP) trade agreement meet in Bangkok this week for another round of closed door negotiations, public health experts and the international medical humanitarian organization - Médecins Sans Frontières (MSF) warn that inclusion of any harmful intellectual property provisions in the agreement could have a severely negative impact on access to affordable generic medicines.
6-19 | Affordable generic versions from China could save millions of people’s lives Médecins Sans Frontières (MSF) today filed a legal patent challenge at China’s State Intellectual Property Office (SIPO), requesting the invalidation of the patent granted to US pharmaceutical corporation Gilead Sciences for the oral hepatitis C medicine velpatasvir.
6-19 | Affordable generic versions from China could save millions of people’s lives Médecins Sans Frontières (MSF) today filed a legal patent challenge at China’s State Intellectual Property Office (SIPO), requesting the invalidation of the patent granted to US pharmaceutical corporation Gilead Sciences for the oral hepatitis C medicine velpatasvir.
Pages
eDonation
Field worker
I LIKE MSF
